TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00498368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Rituximab
Description: Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE/ARB
Description: ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE/ARB
Description: ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid Fish Oil Supplement
Description: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid Fish Oil Supplement
Description: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
Study: NCT02909582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cohen Incision
Description: This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
Study: NCT02282930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH (Acthar) Gel
Description: Injected dose of 80 units subcutaneously twice weekly for 6 months.
Study: NCT00934713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast 4mg once per day for 8 weeks period
Study: NCT02156206

Intervention type: BEHAVIORAL
Intervention: 123 women emergency phone line in Medellin, Colombia
Description: 123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday.
Study: NCT02940899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention: Syracuse University Fir Families Program (SUFFP)
Description: The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
Study: NCT02015104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
Description: TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
Study: NCT02083952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddle Blanket
Description: Two arms involve varying time spent in blanket
Study: NCT02015104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
Description: TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANVAC
Description: A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
Study: NCT01661504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Screening
Description: The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
Study: NCT01642004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT01986517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No feedback
Description: Therapists will receive no feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback after every fourth session
Study: NCT01962389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winsor Laser Catheter
Study: NCT00432185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEP005
Description: 0.25% PEP005 Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEP005
Description: 0.25% PEP005 Gel
Study: NCT00285649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA-SM
Description: HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
Study: NCT02654522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: 1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
Study: NCT02063022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (as per protocol ISG SSG III)
Description: Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
Study: NCT03548701

Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastometry testing
Description: Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities

Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastometry testing
Description: Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
Study: NCT01624701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ex vivo expanded cord blood cells
Description: Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
Study: NCT02873741

Intervention type: PROCEDURE
Intervention: Perianal and Digital Anorectal Exam
Description: The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.

Intervention type: PROCEDURE
Intervention: Cervical Swabs
Description: A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.

Intervention type: PROCEDURE
Intervention: Anal Swabs
Description: The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.

Intervention type: PROCEDURE
Intervention: High Resolution Anoscopy (HRA)
Description: High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
Study: NCT03597464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Voclosporin placebo, oral, 3 capsules twice daily (BID)
Study: NCT02942641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indwelling urethral catheterization (Foley)
Description: Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization (CIC)
Description: Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley
Study: NCT00788944

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood draw
Description: Test Article was not provided to subjects for this study.
Study: NCT04097275

Intervention type: OTHER
Intervention: Skin biopsy
Description: The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.

Intervention type: OTHER
Intervention: Withdraw of blood
Description: Blood will be collected in:~* 1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~* 1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~* 1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing
Study: NCT00596557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
Study: NCT01475643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate
Description: 1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolones acetate
Description: 1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
Study: NCT01997593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal infiltration of ropivacaine
Description: intraperitoneal infiltration of ropivacaine by a special equipment
Study: NCT02243319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904 and HGP1201 co-administraion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904 and HGP1201 co-administraion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904 and HGP1201 co-administraion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904 and HGP1201 co-administraion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904 and HGP1201 co-administraion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904 and HGP1201 co-administraion
Study: NCT04248244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-MM questionnaire
Description: FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
Study: NCT00285649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LVVA-SM
Description: LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Medical Care
Description: Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
Study: NCT04837781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
Study: NCT03272880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arts-Based Programming
Description: This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
Study: NCT04363463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prone position
Description: Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
Study: NCT03712995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 'Cutler-Beard modified with graft'
Description: A tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described.
Study: NCT02315456

Intervention type: PROCEDURE
Group type: OTHER
Intervention: capsulorhexis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: capsulorhexis
Study: NCT04120480

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic test
Description: The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
Study: NCT04273568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular PNF
Description: Rhythmic initiation and repetitive stretching techniques in scapula anterior elevation-posterior depression and anterior depression-posterior elevation patterns were applied twice a week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.
Study: NCT00438776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 2.5mg to 15mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: matching placebo to olanzapine
Study: NCT03252262

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitalize 360
Description: A comprehensive geriatric assessment system and wellness coaching program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitalize 360
Description: A comprehensive geriatric assessment system and wellness coaching program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitalize 360
Description: A comprehensive geriatric assessment system and wellness coaching program.
Study: NCT01071291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niaspan
Description: Niaspan™

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niaspan
Description: Niaspan™

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo
Study: NCT02544698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of PCV13a vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of PCV13a vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: three doses of PCV13a vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: three doses of PCV13a vaccine
Study: NCT02663245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: * Diabetes specific consultation~* Basic training in clinical guidelines~* Platform of communication for professionals~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: * 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~* Basic training in clinical guidelines.~* Platform of communication for professionals.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes.
Study: NCT02663947

Intervention type: DEVICE
Intervention: ultrasonographic measurement of optic nerve sheath diameter
Description: A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
Study: NCT00381108

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Two tablets, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomegranate Tablet
Description: Two tablets, twice daily.
Study: NCT01413867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stapled hemorrhoidopexy
Description: stapled hemorrhoidopexy will be performed using the EEA stapler Covidien

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stapled hemorrhoidopexy
Description: stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery